Metraipolis › archive › dc_580761efcb2a

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis — Europe PMC PMID:33956882

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/33956882
DOI
10.1371/journal.pone.0251170
License (as archived)
CC0-1.0
Archived
2026-11-04T11:50:33.846Z
SHA-256 of the archived text
5c98182db0597ba7def5e737404fc6e9b82d4d32bf9e2c1773133fbdec4d7fe4
Stable URL of this page
https://metraipolis.com/documento/dc_580761efcb2a

How to cite

Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis — Europe PMC PMID:33956882 — Europe PMC (en), https://europepmc.org/article/MED/33956882 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_580761efcb2a (Metraipolis archive dc_580761efcb2a, sha256 5c98182db0597ba7def5e737404fc6e9b82d4d32bf9e2c1773133fbdec4d7fe4)
BibTeX
@misc{dc580761efcb2a,
  title = {Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: A systematic review and meta-analysis — Europe PMC PMID:33956882},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/33956882},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_580761efcb2a; sha256 5c98182db0597ba7def5e737404fc6e9b82d4d32bf9e2c1773133fbdec4d7fe4},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33956882. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Introduction: The recovery of other pathogens in patients with SARS-CoV-2 infection has been reported, either at the time of a SARS-CoV-2 infection diagnosis (co-infection) or subsequently (superinfection). However, data on the prevalence, microbiology, and outcomes of co-infection and superinfection are limited. The purpose of this study was to examine the occurrence of co-infections and superinfections and their outcomes among patients with SARS-CoV-2 infection. Patients and methods: We searched literature databases for studies published from October 1, 2019, through February 8, 2021. We included studies that reported clinical features and outcomes of co-infection or superinfection of SARS-CoV-2 and other pathogens in hospitalized and non-hospitalized patients. We followed PRISMA guidelines, and we registered the protocol with PROSPERO as: CRD42020189763. Results: Of 6639 articles screened, 118 were included in the random effects meta-analysis. The pooled prevalence of co-infection was 19% (95% confidence interval [CI]: 14%-25%, I2 = 98%) and that of superinfection was 24% (95% CI: 19%-30%). Pooled prevalence of pathogen type stratified by co- or superinfection were: viral co-infections, 10% (95% CI: 6%-14%); viral superinfections, 4% (95% CI: 0%-10%); bacterial co-infections, 8% (95% CI: 5%-11%); bacterial superinfections, 20% (95% CI: 13%-28%); fungal co-infections, 4% (95% CI: 2%-7%); and fungal superinfections, 8% (95% CI: 4%-13%). Patients with a co-infection or superinfection had higher odds of dying than those who only had SARS-CoV-2 infection (odds ratio = 3.31, 95% CI: 1.82-5.99). Compared to those with co-infections, patients with superinfections had a higher prevalence of mechanical ventilation (45% [95% CI: 33%-58%] vs. 10% [95% CI: 5%-16%]), but patients with co-infections had a greater average length of hospital stay than those with superinfections (mean = 29.0 days, standard deviation [SD] = 6.7 vs. mean = 16 days, SD = 6.2, respectively). Conclusions: Our study showed that as many as 19% of patients with COVID-19 have co-infections and 24% have superinfections. The presence of either co-infection or superinfection was associated with poor outcomes, including increased mortality. Our findings support the need for diagnostic testing to identify and treat co-occurring respiratory infections among patients with SARS-CoV-2 infection.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-05-06).
Identificativi: PMID 33956882 · PMCID PMC8101968 · DOI 10.1371/journal.pone.0251170.
Pagina: https://europepmc.org/article/MED/33956882 — https://doi.org/10.1371/journal.pone.0251170. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-04T11:50:25.078Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.